UPENDS
28.12.2022 10:56:41 CET | Business Wire | Press release
UPENDS, an e-cigarette brand that prioritizes users’ experience and aims to become the favorite brand for vapers, has recently released its brand new next-gen mesh coil technology and UpBAR GT, the world’s first car concept disposable vape equipped with the next-gen mesh coil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005002/en/
(Photo: Business Wire)
What Does the Next-gen Mesh Coil Mean to the Vape Market?
With the surge of the disposable vape market, countless manufacturers and brands influx into this track, pushing technology innovation quickly. Mesh coil, the key tech of disposable vapes, becomes the essential of tech innovation, which profoundly influences performance like flavor reproduction and puffs. It is obvious that products with stronger next-gen mesh coils will be more competitive in the market.
Next-gen Mesh Coil Comes with Significant Improvements in Performance.
Since the release of its “Mesh Coil is the Future” brand proposition, UPENDS has been dedicated to the innovation of mesh coil technology and has made many breakthroughs. After lab tests and adjustments, UPENDS next-gen mesh coil has been invented successfully. “Compared with traditional mesh coils, its flavor reproduction increased by 38%, puffs increased by 33% and energy efficiency increased by 36% with the same e-liquid capacity”, said Doctor WU, the Chief Product Officer of UPENDS. “We are so excited to release the next-gen mesh coil, and we believe that our customers will be satisfied with the strong performance and longevity it brings.”
UPENDS Makes A Comprehensive Breakthrough in Mesh Coil Technology.
Not only optimizing the coil, UPENDS has also upgraded technologies of the whole cotton coil platform for better performance and quality control. It features a V-shaped air inlet design that can accelerate aerosol delivery, decrease condensate and provide stronger smoke, compared with normal straight channels. Meanwhile, there’s literally no possibility of burnt tastes and oil leakage thanks to its industry-first Tesla value, unique separate air exchange and e-liquid supply channels and multi-layer seal leakage-proof. In addition, it adopts fully-automated manufacturing process technology, aiming to guarantee both production efficiency and stable high quality.
UpBAR GT with Next-gen Mesh Coil is Coming in January 2023.
So what does the next-gen mesh coil bring to UPENDS? UpBAR GT, the first disposable vape equipped with this technology will be the answer. As the “World’s First Car Concept Disposable Vape”, UpBAR GT seeks inspiration from sports cars and stands out from the crowd with its streamlined design and V-shaped grille decorations. GT is the abbreviation of Grand Touring, a type of car designed for high speed and long-distance driving, which also implies the features such as high quality, stability, security and more of UpBAR GT. In addition, there is an eco-friendly version using recycled materials.
About UPENDS
Founded in 2019, UPENDS is an e-cigarette brand dedicated to the field of Electronic Nicotine Delivery Systems. The good reputation of UPENDS as a leading e-cigarette brand in Europe attributes to its excellent manufacturing technology and quality, simple design, and cost-effective features. Currently, UPENDS is expanding its global development. UPENDS persistent pursuit is to prioritize users’ experience and to be Vaper's favorite. For more information, please visit www.upends.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom